Search Results - "Akewanlop, C"

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin by Rugo, H, Barve, A, Waller, C, Bronchud, M.H, Herson, J, Yuan, J, Manikhas, A, Bondarenko, I, Mukhametshina, G, Nemsadze, G, Parra, J, Abesamis Tiambeng, M.L, Baramidze, K, Akewanlop, C, Vynnychenko, I, Sriuranpong, V, Mamillapalli, G, Ray, S, Yanez Ruiz, E.P, Pennella, E

Get full text

AOSP36 PREVALENCE OF DMMR IN SPORADIC COLORECTAL CANCER PATIENTS AT SIRIRAJ HOSPITAL by Korphaisarn, K, Manuyakorn, A, Roothumnong, E, Klaisuban, W, Nimmannit, A, Jinawath, A, Limwongse, C, Akewanlop, C

Get full text

1676P Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience by Umpawan, N., Termsinsuk, P., Kaosombatwattana, U., Akewanlop, C., Korphaisarn, K.

Get full text

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody by AKEWANLOP, Charuwan, WATANABE, Michiaki, SINGH, Baljit, WALKER, Mignon, KUFE, Donald W, HAYES, Daniel F

“…Human epithelial mucin, MUC-1, is commonly expressed in adenocarcinoma including 80% of breast cancers. erbB-2 is overexpressed in approximately 30% of breast…”
Get full text

1961P Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center by Thongthammachat, K., Chantharassamee, J., Muangsomboon, S., Nimmannit, A., Chandhanayingyong, C., Akewanlop, C.

Get full text

Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer by Korphaisarn, K., Pongpaibul, A., Sukhokanjanachusak, K., Akewanlop, C.

Get full text

557P - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer by Korphaisarn, K., Pongpaibul, A., Sukhokanjanachusak, K., Akewanlop, C.

“…Loss of caudal-type homeobox transcription factor-2 (CDX-2) expression in colorectal cancers (CRC) has recently been proposed as a predictive biomarker for…”
Get full text

590P - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer by Sukhokanjanachusak, K., Korphaisarn, K., Akewanlop, C., Pongpaibul, A., Nimmannit, A.

“…Overall colorectal cancer (CRC) incidence and mortality are declining due to cancer screening in older patients population, however, the incidence of CRC is…”
Get full text

Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer by Sukhokanjanachusak, K., Korphaisarn, K., Akewanlop, C., Pongpaibul, A., Nimmannit, A.

Get full text

557PLoss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer by Korphaisarn, K, Pongpaibul, A, Sukhokanjanachusak, K, Akewanlop, C

“…Abstract Background Loss of caudal-type homeobox transcription factor-2 (CDX-2) expression in colorectal cancers (CRC) has recently been proposed as a…”
Get full text

590PComparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer by Sukhokanjanachusak, K, Korphaisarn, K, Akewanlop, C, Pongpaibul, A, Nimmannit, A

“…Abstract Background Overall colorectal cancer (CRC) incidence and mortality are declining due to cancer screening in older patients population, however, the…”
Get full text

EE3 Cost-Utility Analysis of Xelox Plus Bevacizumab Versus Xelox for Metastatic Colorectal Cancer Treatment in Thailand by Wanitphisitphan, C, Kositamongkol, C, Korphaisarn, K, Akewanlop, C, Srimuninnimit, V, Phisalprapa, P

Get full text

1830P Association of body composition measured by bioelectrical impedance analysis and hematologic adverse events in early-stage breast cancer patients receiving chemotherapy by Thanestada, J., Srinonprasert, V., Nimmannit, A., Korphaisarn, K., Pramyothin, P., Akewanlop, C.

Get full text

296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA by Wu, Y-L., Tsuboi, M., Grohe, C., John, T., Majem Tarruella, M., Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vinh Vu, H., Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A., Huang, X., Herbst, R.S.

Get full text

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA by Tsuboi, M., Wu, Y-L., Grohe, C., John, T., Tarruella, M. Majem, Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vu, H. Vinh, Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A.L., Huang, X., Herbst, R.S.

Get full text

1450P - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection by Tsuboi, M., Herbst, R.S., John, T., Grohe, C., Majem, M., Goldman, J.W., Kim, S.-W., Yu, C.-J., Miziara, J.E.A., Novello, S., Urban, D., Akewanlop, C., Öztürk, A., Quang, B.V., Kowalski, D., Marmol, D., Marotti, M., Laus, G., Wu, Y.-L.

“…Data on the frequency of EGFR mutations in patients (pts) with NSCLC potentially eligible for adjuvant therapy are limited. Osimertinib, a 3rd-generation,…”
Get full text

Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection by Tsuboi, M., Herbst, R.S., John, T., Grohe, C., Majem, M., Goldman, J.W., Kim, S.-W., Yu, C.-J., Miziara, J.E.A., Novello, S., Urban, D., Akewanlop, C., Öztürk, A., Quang, B.V., Kowalski, D., Marmol, D., Marotti, M., Laus, G., Wu, Y.-L.

Get full text

356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence by Tsuboi, M., Wu, Y-L., He, J., John, T., Grohe, C., Majem, M., Goldman, J.W., Laktionov, K., Kim, S-W., Kato, T., Vu, H.V., Akewanlop, C., Yu, C-J., de Marinis, F., Domine, M., Shepherd, F.A., Yan, C., Atasoy, A., Herbst, R.

Get full text

LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence by Tsuboi, M., Wu, Y-L., He, J., John, T., Grohe, C., Majem, M., Goldman, J.W., Laktionov, K., Kim, S-W., Kato, T., Vu, H.V., Akewanlop, C., Yu, C-J., de Marinis, F., Domine, M., Shepherd, F.A., Yan, C., Atasoy, A., Herbst, R.

Get full text

1450PFrequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection by Tsuboi, M, Herbst, R S, John, T, Grohe, C, Majem, M, Goldman, J W, Kim, S-W, Yu, C-J, Miziara, J E A, Novello, S, Urban, D, Akewanlop, C, Öztürk, A, Quang, B V, Kowalski, D, Marmol, D, Marotti, M, Laus, G, Wu, Y-L

“…Abstract Background Data on the frequency of EGFR mutations in patients (pts) with NSCLC potentially eligible for adjuvant therapy are limited. Osimertinib, a…”
Get full text